ESC2015:两种新的有创冠脉微血管阻力指数

2015-09-08 河北医科大学第二医院 傅向华 魏立业 编译 中国医学论坛报

2015欧洲心脏病学会年会(ESC2015)专题报道 冠状动脉微血管阻力MVR)作为一个心肌梗死后评价预后和治疗方案的指标被广泛应用。目前还没有CMVR有创测量的金标准。英国学者比较了两种新的在心导管室进行CMVR有创测量的手段:多普勒诱导充血的微血管阻力(hMR)和热稀释法微血管阻力指数(IMR),与使用高分辨率心脏磁共振成像(CMR)测量的心肌灌注储备指数(MPRI)进行比较。结果显

2015欧洲心脏病学会年会(ESC2015)专题报道

冠状动脉微血管阻力MVR)作为一个心肌梗死后评价预后和治疗方案的指标被广泛应用。目前还没有CMVR有创测量的金标准。英国学者比较了两种新的在心导管室进行CMVR有创测量的手段:多普勒诱导充血的微血管阻力(hMR)和热稀释法微血管阻力指数(IMR),与使用高分辨率心脏磁共振成像(CMR)测量的心肌灌注储备指数(MPRI)进行比较。结果显示,在心导管室准确评估CMVR是可行的、安全的和快速的。研究中首次同时评估了两种CMVR测量方法的诊断准确性,证实了多普勒诱导的hMR比IMR在现存的预测CMVR的有创和无创性参考标准(CFR和MPR)具有更优越的诊断准确性。

研究入选了37例患者(61±10岁),63%为急性冠脉综合症(ACS)患者。共在45支冠状动脉中同时行冠脉内压力、多普勒流速和冷丸通过时间测量,使用Volcano Combowire 和St Jude压力导丝,分别在静息和静脉注射腺苷充血时测量。测量在伴有显著的冠状动脉狭窄(稳定心绞痛和ACS) 的患者中行PCI治疗后进行。在临床情况允许时,第二次测量是在一个正常的参考血管中进行。我们使用标准的定义计算,由热稀释法和多普勒法测量的平均冠状动脉血流储备(CFR)、hMR和IMR。在尽可能接近有创测量的时间进行3T-CMR灌注扫描和在如前所述的相应节段行MPRI计算。在ACS患者中,相应区域的局部室壁运动和整体左心室射血分数(LVEF) (来自CMR动态影像),和梗塞大小(来自CMR对比剂增强图像)也被计算。

结果为,hMR与IMR相关(r = 0.67,p< 0.001)。在ACS患者中,LVEF、梗塞大小和局部室壁运动都是单变量的预测因子。然而hMR是局部室壁运动唯一的独立预测指标。使用ROC曲线分析,hMR比IMR预测平均CFR具有更高的诊断准确性(曲线下面积0.79和0.59,p < 0.79), hMR与IMR可以分别预测MPRI(面积曲线0.97和0.84,p = 0.09)。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1816409, encodeId=260f18164097a, content=<a href='/topic/show?id=7c029e64889' target=_blank style='color:#2F92EE;'>#阻力指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97648, encryptionId=7c029e64889, topicName=阻力指数)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Sep 12 10:05:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365290, encodeId=df551365290ba, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36521, encodeId=2c913652121, content=不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a071647265, createdName=chilam216, createdTime=Wed Sep 09 00:26:00 CST 2015, time=2015-09-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1816409, encodeId=260f18164097a, content=<a href='/topic/show?id=7c029e64889' target=_blank style='color:#2F92EE;'>#阻力指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97648, encryptionId=7c029e64889, topicName=阻力指数)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Sep 12 10:05:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365290, encodeId=df551365290ba, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36521, encodeId=2c913652121, content=不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a071647265, createdName=chilam216, createdTime=Wed Sep 09 00:26:00 CST 2015, time=2015-09-09, status=1, ipAttribution=)]
    2015-09-10 mgqwxj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1816409, encodeId=260f18164097a, content=<a href='/topic/show?id=7c029e64889' target=_blank style='color:#2F92EE;'>#阻力指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97648, encryptionId=7c029e64889, topicName=阻力指数)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Sep 12 10:05:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365290, encodeId=df551365290ba, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36521, encodeId=2c913652121, content=不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a071647265, createdName=chilam216, createdTime=Wed Sep 09 00:26:00 CST 2015, time=2015-09-09, status=1, ipAttribution=)]
    2015-09-09 chilam216

    不錯

    0